After-Hours Movers 12/03: (HQY) (GPRO) (MA) Higher; (RVNC) (RLMD) (RAPT) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Harry and Meghan surprised by King Charles' letter on their status
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Revance Therapeutics (RVNC) Reports Publication of Pooled Results from Phase 3 Trials for Glabellar Lines
December 5, 2019 8:02 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of the pooled data from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies (SAKURA 1 and SAKURA 2) evaluating Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI) for the treatment of moderate to severe glabellar (frown)... More
Immunomedics (IMMU) Prices 14.286M Share Common Offering at $17.50/Sh
December 5, 2019 5:51 AM ESTImmunomedics, Inc. (NASDAQ: IMMU) today announced the pricing of an... More
SunTrust Reiterates Buy Rating on Zscaler (ZS) Following 1Q Beat
December 4, 2019 8:19 AM ESTSunTrust analyst Joel Fishbein Jr. reiterated a Buy rating and $73.00 price target on Zscaler (NASDAQ: ZS) following the company's 1Q earnings report. Zscaler delivered a slight beat and raise with margin upside.
The Company reported $93.6MM of revenue for 1Q20, beating consensus at... More
Raptor Technology Group, Inc. (RAPT) Announces Rodney Young as CFO
December 4, 2019 8:03 AM ESTRAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the appointment of Rodney Young as chief financial officer effective December 2, 2019.
As a newly public company, we are thrilled to welcome Rodney to RAPT, said Brian Wong, M.D., Ph.D., president and CEO of RAPT... More
Revance Therapeutics (RVNC) Prices 6.5M Share Offering at $17/Sh
December 4, 2019 7:42 AM ESTRevance Therapeutics, Inc. (NASDAQ: RVNC) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $17.00 per share. Revance has granted the underwriters a 30-day option to purchase up to an aggregate of... More
Relmada Therapeutics (RLMD) Prices 3.33M Share Common Offering at $33/Sh
December 4, 2019 5:41 AM ESTRelmada Therapeutics, Inc. (NASDAQ: RLMD) today announced the pricing of an offering of 3,333,334 shares of its common stock at a public offering price of $30.00 per share in an underwritten offering. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and... More
